Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW.

Cancer. 2018 May 15;124(10):2174-2183. doi: 10.1002/cncr.31304. Epub 2018 Mar 13.

2.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.

Invest New Drugs. 2018 Jan 8. doi: 10.1007/s10637-017-0551-z. [Epub ahead of print]

PMID:
29313279
3.

Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data.

Mittapalli RK, Marroum P, Qiu Y, Apfelbaum K, Xiong H.

Pharm Res. 2017 Jul;34(7):1527-1533. doi: 10.1007/s11095-017-2179-2. Epub 2017 May 16.

PMID:
28512718
4.

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.

Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, DeLuca A, Mittapalli RK, Munasinghe W, He L, Zalcberg JR, Ngan SY, Komarnitsky P, Michael M.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):418-426. doi: 10.1016/S2468-1253(17)30012-2. Epub 2017 Mar 27.

PMID:
28497757
5.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.

Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS.

J Thorac Oncol. 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29.

6.

Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.

Munasinghe WP, Mittapalli RK, Li H, Hoffman DM, Holen KD, Menon RM, Xiong H.

Cancer Chemother Pharmacol. 2017 May;79(5):915-922. doi: 10.1007/s00280-017-3284-y. Epub 2017 Mar 27.

PMID:
28349167
7.

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.

Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H.

Cancer Chemother Pharmacol. 2017 Mar;79(3):587-594. doi: 10.1007/s00280-017-3262-4. Epub 2017 Feb 28.

PMID:
28247011
8.

Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.

Mittapalli RK, Nuthalapati S, Delke DeBord AE, Xiong H.

Pharm Res. 2017 Jun;34(6):1187-1192. doi: 10.1007/s11095-017-2133-3. Epub 2017 Feb 27.

PMID:
28243955
9.

Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors.

Mittapalli RK, Adkins CE, Bohn KA, Mohammad AS, Lockman JA, Lockman PR.

Cancer Res. 2017 Jan 15;77(2):238-246. doi: 10.1158/0008-5472.CAN-16-1711. Epub 2016 Nov 4.

10.

Semi-automated rapid quantification of brain vessel density utilizing fluorescent microscopy.

Bohn KA, Adkins CE, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Shah N, Dolan EL, Nounou MI, Lockman PR.

J Neurosci Methods. 2016 Sep 1;270:124-131. doi: 10.1016/j.jneumeth.2016.06.012. Epub 2016 Jun 16.

11.

ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.

Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, Elmquist WF, Becher OJ.

Mol Cancer Ther. 2016 May;15(5):819-29. doi: 10.1158/1535-7163.MCT-15-0093. Epub 2016 Feb 16.

12.

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.

Vaidhyanathan S, Wilken-Resman B, Ma DJ, Parrish KE, Mittapalli RK, Carlson BL, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2016 Feb;356(2):251-9. doi: 10.1124/jpet.115.229393. Epub 2015 Nov 24.

13.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. Epub 2015 Oct 5.

14.

Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.

Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN.

Neuro Oncol. 2016 Jan;18(1):27-36. doi: 10.1093/neuonc/nov164. Epub 2015 Sep 10. Review.

15.

Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.

Parrish KE, Pokorny J, Mittapalli RK, Bakken K, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2015 Nov;355(2):264-71. doi: 10.1124/jpet.115.228213. Epub 2015 Sep 9.

17.

Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.

Gummadi T, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, Dudek AZ.

Melanoma Res. 2015 Feb;25(1):75-9. doi: 10.1097/CMR.0000000000000133.

PMID:
25426645
18.

A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier.

Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan R, Lockman PR.

Cancer Prev Res (Phila). 2015 Jan;8(1):68-76. doi: 10.1158/1940-6207.CAPR-14-0225. Epub 2014 Oct 27.

19.

Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.

Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF.

Drug Metab Dispos. 2014 Aug;42(8):1292-300. doi: 10.1124/dmd.114.058339. Epub 2014 May 29.

20.

Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.

Oberoi RK, Mittapalli RK, Fisher J, Elmquist WF.

Chromatographia. 2013 Dec 1;76(23-24). doi: 10.1007/s10337-013-2528-1.

21.

P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model.

Adkins CE, Mittapalli RK, Manda VK, Nounou MI, Mohammad AS, Terrell TB, Bohn KA, Yasemin C, Grothe TR, Lockman JA, Lockman PR.

Front Pharmacol. 2013 Nov 4;4:136. doi: 10.3389/fphar.2013.00136. eCollection 2013.

22.

Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.

Oberoi RK, Mittapalli RK, Elmquist WF.

J Pharmacol Exp Ther. 2013 Dec;347(3):755-64. doi: 10.1124/jpet.113.208959. Epub 2013 Oct 10.

23.

Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.

Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, Qhattal HS, Geldenhuys WJ, Palmieri D, Steeg PS, Smith QR, Lockman PR.

Mol Cancer Ther. 2013 Nov;12(11):2389-99. doi: 10.1158/1535-7163.MCT-13-0132. Epub 2013 Sep 3.

24.

Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood-brain barrier.

Mittapalli RK, Manda VK, Bohn KA, Adkins CE, Lockman PR.

J Neurosci Methods. 2013 Sep 30;219(1):188-95. doi: 10.1016/j.jneumeth.2013.07.001. Epub 2013 Aug 2.

25.

Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.

Sane R, Agarwal S, Mittapalli RK, Elmquist WF.

J Pharmacol Exp Ther. 2013 Apr;345(1):111-24. doi: 10.1124/jpet.112.199786. Epub 2013 Feb 8.

26.

Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.

Sane R, Mittapalli RK, Elmquist WF.

J Pharm Sci. 2013 Apr;102(4):1343-54. doi: 10.1002/jps.23450. Epub 2013 Jan 18.

27.

Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.

Dudek AZ, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, Agarwal S, Elmquist WF.

Clin Genitourin Cancer. 2013 Jun;11(2):155-60. doi: 10.1016/j.clgc.2012.11.001. Epub 2012 Dec 21.

28.

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.

Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF.

J Pharmacol Exp Ther. 2013 Mar;344(3):655-64. doi: 10.1124/jpet.112.201475. Epub 2012 Dec 17.

29.

Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.

Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, Decker SA, Santacruz KS, Pokorny JL, Sarkaria JN, Elmquist WF, Ohlfest JR.

Mol Cancer Ther. 2012 Oct;11(10):2183-92. doi: 10.1158/1535-7163.MCT-12-0552. Epub 2012 Aug 13.

30.

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).

Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF.

J Pharmacol Exp Ther. 2012 Jul;342(1):33-40. doi: 10.1124/jpet.112.192195. Epub 2012 Mar 27.

31.

Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.

Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF.

Drug Metab Dispos. 2012 Jun;40(6):1164-9. doi: 10.1124/dmd.112.044719. Epub 2012 Mar 8.

32.

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, Polli JW, Castellino S, Rubin SD, Lockman PR, Steeg PS, Smith QR.

Pharm Res. 2012 Mar;29(3):770-81. doi: 10.1007/s11095-011-0601-8. Epub 2011 Oct 20.

33.

Varying efficacy of superdisintegrants in orally disintegrating tablets among different manufacturers.

Mittapalli RK, Qhattal HS, Lockman PR, Yamsani MR.

Pharmazie. 2010 Nov;65(11):805-10.

PMID:
21155386
34.

Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules.

Mittapalli RK, Manda VK, Adkins CE, Geldenhuys WJ, Lockman PR.

Ther Deliv. 2010 Dec;1(6):775-84. Review.

PMID:
22834013
35.

Nicotine and cotinine increases the brain penetration of saquinavir in rat.

Manda VK, Mittapalli RK, Bohn KA, Adkins CE, Lockman PR.

J Neurochem. 2010 Dec;115(6):1495-507. doi: 10.1111/j.1471-4159.2010.07054.x. Epub 2010 Nov 11.

36.

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR.

Clin Cancer Res. 2010 Dec 1;16(23):5664-78. doi: 10.1158/1078-0432.CCR-10-1564. Epub 2010 Sep 9.

37.

Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity.

Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR.

J Neurochem. 2010 Oct;115(2):515-25. doi: 10.1111/j.1471-4159.2010.06948.x. Epub 2010 Aug 30.

38.

Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter.

Geldenhuys WJ, Manda VK, Mittapalli RK, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD, Lockman PR.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):870-7. doi: 10.1016/j.bmcl.2009.12.079. Epub 2009 Dec 28.

39.

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.

Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR, Steeg PS.

Clin Cancer Res. 2009 Oct 1;15(19):6148-57. doi: 10.1158/1078-0432.CCR-09-1039. Epub 2009 Sep 29.

40.

Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.

Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, Mittapalli RK, Palmieri D, Steeg PS, Lockman PR, Smith QR.

Pharm Res. 2009 Nov;26(11):2486-94. doi: 10.1007/s11095-009-9964-5. Epub 2009 Sep 23.

41.

bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter.

Zhang Z, Lockman PR, Mittapalli RK, Allen DD, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5622-5. doi: 10.1016/j.bmcl.2008.08.099. Epub 2008 Aug 30.

42.

Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier.

Lockman PR, Manda VK, Geldenhuys WJ, Mittapalli RK, Thomas F, Albayati ZF, Crooks PA, Dwoskin LP, Allen DD.

J Pharmacol Exp Ther. 2008 Jan;324(1):244-50. Epub 2007 Oct 5.

Supplemental Content

Loading ...
Support Center